Plaque PsoriasisDREAMNCT07039110
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
An observational study of Plaque Psoriasis, run by AbbVie at 84 sites in 8 countries.
Trial summary
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Plaque Psoriasis
- How many people
- 700 participants
- Where
- 84 sitesin 8 countries
- Study dates
- 9 Sep 2025to Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult participants with moderate to severe plaque psoriasis who are prescribed risankizumab by their physician.
Who may be able to join
- Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
- Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
- Decision to treat with risankizumab is made prior to and independently of study participation.
Who cannot join
- History of a sleep disorder diagnosis which the patient is currently being treated for.
- Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
- Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.
Trial locations and contacts
84 sites in 8 countries. Contact the study team or a site near you to ask about taking part.
84 sites in 8 countries
Japan20 sites, 20 recruiting
- Recruiting
Asahikawa Medical University Hospital /ID# 278981
Asahikawa-shi, Hokkaido, 078-8510
- Recruiting
Juntendo University Hospital /ID# 278495
Bunkyo-ku, Tokyo, 113-8431
- Recruiting
Fukuoka University Hospital /ID# 278600
Fukuoka, 814-0180
- Recruiting
University of the Ryukyus Hospital /ID# 278256
Ginowan-shi, Okinawa, 901-2725
- Recruiting
Tokai University Hospital /ID# 278294
Isehara, Kanagawa, 259-1193
- Recruiting
Kagoshima University Hospital /ID# 278514
Kagoshima, Kagoshima-ken, 890-8520
- Recruiting
Kawasaki Medical School Hospital /ID# 278259
Kurashiki, Okayama-ken, 701-0192
- Recruiting
University Hospital Kyoto Prefectural University of Medicine /ID# 278962
Kyoto, Kyoto, 602-8566
- Recruiting
Gunma University Hospital /ID# 278497
Maebashi, Gunma, 371-8511
- Recruiting
Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 278434
Osaka, 550-0006
- Recruiting
Kindai University Hospital /ID# 278258
Sakai-shi, Osaka, 590-0197
- Recruiting
Hokkaido University Hospital /ID# 278260
Sapporo, Hokkaido, 060-8648
- Recruiting
Hosui General Medical Clinic /ID# 279520
Sapporo, Hokkaido, 0640807
- Recruiting
Jichi Medical University Hospital /ID# 280236
Shimotsuke-shi, Tochigi, 329-0498
- Recruiting
Seibo Hospital /ID# 279522
Shinjuku-ku, Tokyo, 161-8521
- Recruiting
The University of Osaka Hospital /ID# 278436
Suita-shi, Osaka, 565-0871
- Recruiting
Tokyo Yamate Medical Center /ID# 278960
Tokyo, 169-0073
- Recruiting
Teikyo University Hospital /ID# 278228
Tokyo, 173-8605
- Recruiting
Nihon University Itabashi Hospital /ID# 279916
Tokyo, 173-8610
- Recruiting
Yokohama City University Hospital /ID# 278257
Yokohama, Kanagawa, 236-0004
Canada18 sites, 17 recruiting
- Recruiting
Cca Medical Research /ID# 276944
Ajax, Ontario, L1S 7K8
- Recruiting
Quinte dermatology /ID# 277497
Belleville, Ontario, K8N 2S9
- Recruiting
Dermatology Research Institute - Blackfoot Trail /ID# 276722
Calgary, Alberta, T2J 7E1
- Recruiting
Rejuvenation Dermatology - Edmonton Downtown /ID# 276688
Edmonton, Alberta, T5J 3S9
- Completed
Dermatrials Research /ID# 276714
Hamilton, Ontario, L8N 1Y2
- Recruiting
Lovegrove Dermatology /ID# 276797
London, Ontario, N6A 5R9
- Recruiting
Lynderm Research Inc /ID# 276755
Markham, Ontario, L3P 1X2
- Recruiting
Rejuvenation Dermatology Clinic Oakville /ID# 277492
Oakville, Ontario, L6H 6P8
- Recruiting
JRB Research inc. /ID# 277730
Ottawa, Ontario, K1K 4L2
- Recruiting
Factor Dermatology /ID# 278610
Ottawa, Ontario, K2A 2M3
- Recruiting
SKiN Centre for Dermatology /ID# 277594
Peterborough, Ontario, K9J 5K2
- Recruiting
Dre Angelique Gagne-Henley M.D. inc. /ID# 276687
Saint-Jérôme, Quebec, J7Z 7E2
- Recruiting
Eternal Springtime Dermatology /ID# 278598
Thunder Bay, Ontario, P7C 4Y7
- Recruiting
North York Research /ID# 276835
Toronto, Ontario, M2N 3A6
- Recruiting
Avenue Research Group /ID# 276846
Toronto, Ontario, M5N 1A8
- Recruiting
Centre for Medical and Surgical Dermatology /ID# 278775
Whitby, Ontario, L1N 8M7
- Recruiting
Winnipeg Clinic /ID# 276751
Winnipeg, Manitoba, R3C 1T6
- Recruiting
Wiseman Dermatology Research /ID# 276847
Winnipeg, Manitoba, R3M 3Z4
Germany12 sites, 11 recruiting
- Recruiting
Klinikum Dortmund Klinikzentrum Mitte /ID# 284856
Dortmund, North Rhine-Westphalia, 44137
- Recruiting
Dr. med. Moritz Huber und Dr. med. Martin Heister /ID# 277627
Friedrichshafen, Baden-Wurttemberg, 88046
- Recruiting
Universitaetsklinikum Hamburg-Eppendorf /ID# 277164
Hamburg, 20246
- Recruiting
Cutaneum /ID# 277294
Hamburg, 20249
- Recruiting
Private Practice - Dr. Mario Pawlak /ID# 277465
Heilbad Heiligenstadt, 37308
- Recruiting
Dermakulm /Id# 277864
Kulmbach, Bavaria, 95326
- Completed
Hautarztpraxis Dr. Med. Ulrike Wiemers / Dr. Med. Franca Wiemers /ID# 277821
Leipzig, 04317
- Recruiting
Universitaetsmedizin Mainz /ID# 278229
Mainz, Rhineland-Palatinate, 55131
- Recruiting
Dermatologie Moelln Praxis Dr. Bodo Segert /ID# 277628
Mölln, Schleswig-Holstein, 23879
- Recruiting
Dermazent /Id# 280327
Munich, Bavaria, 80331
- Recruiting
Hautaerzte am Nauener Tor /ID# 284579
Potsdam, Brandenburg, 14469
- Recruiting
Hautarztpraxis Schwelm /ID# 277464
Schwelm, 58332
Greece9 sites, 9 recruiting
- Recruiting
General Hospital Andreas Syggros /ID# 276826
Athens, Attica, 16121
- Recruiting
General Hospital Andreas Syggros /ID# 279246
Athens, Attica, 16121
- Recruiting
University General Hospital Attikon /ID# 278389
Chaïdári, Attica, 12462
- Recruiting
The University Hospital of Larissa /ID# 276576
Larissa, Thessaly, 41110
- Recruiting
Tzaneio Prefecture General Hospital of Piraeus /ID# 276532
Piraeus, Attica, 18536
- Recruiting
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 276488
Thessaloniki, 54643
- Recruiting
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 276489
Thessaloniki, 54643
- Recruiting
Papageorgiou General Hospital /ID# 276487
Thessaloniki, 56429
- Recruiting
Asklipieio General Hospital of Voula /ID# 278235
Voula, Attica, 16673
France7 sites, 7 recruiting
- Recruiting
Dr. Rima Mohty /ID# 279951
Beauvais, Oise, 60000
- Recruiting
Hopital Ambroise-Pare /ID# 280402
Boulogne-Billancourt, 92104
- Recruiting
Chu de Dijon /ID# 279900
Dijon, Bourgogne-Franche-Comté, 21000
- Recruiting
Centre Hospitalier Du Mans /ID# 279899
Le Mans, Sarthe, 72037
- Recruiting
Centre Hospitalier de Niort Georges Renon /ID# 279604
Niort, Deux-Sevres, 79021
- Recruiting
Hopitaux Drome Nord - Romans /ID# 278109
Romans-sur-Isère, Drome, 26102
- Recruiting
Hopital d'Instruction des Armees Sainte-Anne /ID# 278106
Toulon, Var, 83800
Spain7 sites, 7 recruiting
- Recruiting
Hospital General Universitario Santa Maria Del Rosell /ID# 277894
Cartagena, Murcia, 30203
- Recruiting
Hospital Clinico Universitario Virgen de la Arrixaca /ID# 283338
El Palmar, Murcia, 30120
- Recruiting
Hospital Universitario de Leon /ID# 277895
León, Leon, 24080
- Recruiting
Hospital Regional Universitario de Malaga /ID# 277220
Málaga, Andalusia, 29010
- Recruiting
Hospital General Universitario Morales Meseguer /ID# 283339
Murcia, 30008
- Recruiting
Complejo Hospitalario Universitario de Pontevedra /ID# 278085
Pontevedra, 36071
- Recruiting
Hospital Universitario De Toledo /ID# 277896
Toledo, 45007
Czechia6 sites, 6 recruiting
- Recruiting
Fakultni Nemocnice U Sv. Anny V Brne /ID# 275799
Brno, Brno-mesto, 656 91
- Recruiting
Nemocnice Ceske Budejovice /ID# 275541
České Budějovice, 370 01
- Recruiting
Dermafit Centrum /ID# 275897
Pilsen, Plzeň Region, 323 00
Site Coordinator, +420 377 534 145
- Recruiting
Fakultni nemocnice Bulovka /ID# 275540
Prague, Central Bohemia, 180 81
- Recruiting
Dermamedest /ID# 275898
Prague, Praha 2, 120 00
- Recruiting
Fakultni nemocnice Kralovske Vinohrady /ID# 275800
Prague, 100 34
Italy5 sites, 5 recruiting
- Recruiting
Ospedale San Martino /ID# 278984
Genova, 16132
- Recruiting
ASL 1 Abruzzo - Ospedale regionale San Salvatore /ID# 277341
L’Aquila, L Aquila, 67100
- Recruiting
IRCCS Ospedale San Raffaele /ID# 277342
Milan, Milano, 20132
- Recruiting
Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 277713
Naples, Napoli, 80138
- Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 278080
Rome, Roma, 00168
About this study
Official title: The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.
Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide.
Read more
Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
- Conditions
- Plaque Psoriasis
- Keywords
- Plaque Psoriasis, Moderate to Severe Plaque Psoriasis, Risankizumab
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Risankizumab | Participants will receive risankizumab as prescribed by their physician according to local label. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1
DLQI (Dermatology Life Quality Index) assesses symptoms and impacts of dermatologic diseases on quality of life. DLQI scores range from 0 (no at all) to 1 (a little).
Measured: At 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2025
- Study start9 Sep 2025
- Primary completionMar 2028 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Plaque PsoriasisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 700 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07039110
- Sponsor's protocol ID
- P25-187
- Acronym
- DREAM
- Status last verified
- Sep 2026
- First submitted
- 18 Jun 2025
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)
- ClinicalTrials.gov ID
- NCT07039110
- Acronym / sponsor ID
- DREAM / P25-187
- Conditions
- Plaque Psoriasis
- Keywords
- Plaque Psoriasis, Moderate to Severe Plaque Psoriasis, Risankizumab
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 700 participants (estimated)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 9 Sep 2025 (actual)
- Primary completion
- Mar 2028 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 26 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.
Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide.
Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Risankizumab | – | –Participants will receive risankizumab as prescribed by their physician according to local label. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult participants with moderate to severe plaque psoriasis who are prescribed risankizumab by their physician.
Key inclusion criteria (3 listed)
- Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
- Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
- Decision to treat with risankizumab is made prior to and independently of study participation.
Key exclusion criteria (3 listed)
- History of a sleep disorder diagnosis which the patient is currently being treated for.
- Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
- Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Proportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1
Time frame: At 12 months
DLQI (Dermatology Life Quality Index) assesses symptoms and impacts of dermatologic diseases on quality of life. DLQI scores range from 0 (no at all) to 1 (a little).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Plaque Psoriasis
Active, not recruitingPhase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Not yet recruitingPhase 3
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Palmoplantar Psoriasis
RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Psoriasis, Overweight or Obesity
Active, not recruitingPhase 3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
ABBVIE INC. study director
AbbVie
84 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Plaque Psoriasis, run by AbbVie at 84 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 84 sites in Japan, Canada, Germany, Greece, France and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julieta Gonzalez Blanco (844-663-3742, julieta.gonzalezblanco@abbvie.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1 (time frame: At 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.